These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 30991987)

  • 1. The impact of personalised risk information compared to a positive/negative result on informed choice and intention to undergo colonoscopy following colorectal Cancer screening in Scotland (PERICCS) - a randomised controlled trial: study protocol.
    Steele RJC; Digby J; Chambers JA; O'Carroll RE
    BMC Public Health; 2019 Apr; 19(1):411. PubMed ID: 30991987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of hypothetical PErsonalised Risk Information on informed choice and intention to undergo Colorectal Cancer screening colonoscopy in Scotland (PERICCS)-a randomised controlled trial.
    Digby J; O'Carroll RE; Chambers JA; Steele RJC
    BMC Med; 2020 Oct; 18(1):285. PubMed ID: 33076932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motives for non-adherence to colonoscopy advice after a positive colorectal cancer screening test result: a qualitative study.
    Bertels L; Lucassen P; van Asselt K; Dekker E; van Weert H; Knottnerus B
    Scand J Prim Health Care; 2020 Dec; 38(4):487-498. PubMed ID: 33185121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial.
    Chen H; Li N; Shi J; Ren J; Liu C; Zhang Y; Jiang Z; Zhang Z; Dai M
    BMJ Open; 2019 Apr; 9(4):e025935. PubMed ID: 31005927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A digital intake tool to avert outpatient visits in a FIT-based colorectal cancer screening population: study protocol of a multicentre, prospective non-randomized trial - the DIT-trial.
    Marijnissen FE; de Jonge PJF; Erler NS; Ismail SY; Lansdorp-Vogelaar I; Spaander MCW
    BMC Gastroenterol; 2024 Jan; 24(1):38. PubMed ID: 38238726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the utility and acceptability of Faecal immunochemical testing (FIT) as a novel intervention for the improvement of colorectal Cancer (CRC) surveillance in individuals with lynch syndrome (FIT for lynch study): a single-arm, prospective, multi-centre, non-randomised study.
    Lincoln A; Benton S; Piggott C; North BV; Rigney J; Young C; Quirke P; Sasieni P; Monahan KJ
    BMC Cancer; 2022 Nov; 22(1):1144. PubMed ID: 36344941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalised risk communication for informed decision making about taking screening tests.
    Edwards AG; Evans R; Dundon J; Haigh S; Hood K; Elwyn GJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD001865. PubMed ID: 17054144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of presenting information about invasive follow-up testing on individuals' noninvasive colorectal cancer screening participation decision: results from a discrete choice experiment.
    Benning TM; Dellaert BG; Severens JL; Dirksen CD
    Value Health; 2014 Jul; 17(5):578-87. PubMed ID: 25128051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial.
    Walker JG; Macrae F; Winship I; Oberoi J; Saya S; Milton S; Bickerstaffe A; Dowty JG; De Abreu Lourenço R; Clark M; Galloway L; Fishman G; Walter FM; Flander L; Chondros P; Ait Ouakrim D; Pirotta M; Trevena L; Jenkins MA; Emery JD
    Trials; 2018 Jul; 19(1):397. PubMed ID: 30045764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of including quantitative information in a decision aid for colorectal cancer screening: A randomized controlled trial.
    Schwartz PH; Imperiale TF; Perkins SM; Schmidt KK; Althouse S; Rawl SM
    Patient Educ Couns; 2019 Apr; 102(4):726-734. PubMed ID: 30578103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys.
    Wong MC; John GK; Hirai HW; Lam TY; Luk AK; Ching JY; Ng SS; Chan FK; Griffiths SM; Sung JJ
    Cancer Causes Control; 2012 Sep; 23(9):1541-8. PubMed ID: 22836914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychosocial consequences of receiving false-positive colorectal cancer screening results: a qualitative study.
    Toft EL; Kaae SE; Malmqvist J; Brodersen J
    Scand J Prim Health Care; 2019 Jun; 37(2):145-154. PubMed ID: 31079520
    [No Abstract]   [Full Text] [Related]  

  • 15. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting improved compliance towards colonoscopy in individuals with positive faecal immunochemical test (FIT).
    Lim TZ; Lau J; Wong GJ; Tan LY; Chang YJ; Natarajan K; Yi H; Wong ML; Tan KK
    Cancer Med; 2021 Nov; 10(21):7735-7746. PubMed ID: 34519182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive family history of colorectal cancer in a general practice setting [FRIDA.Frankfurt]: study protocol of a of a cross-sectional study.
    Siebenhofer A; Plath J; Taubenroth M; Singer S; Hechtner M; Dahlhaus A; Rauck S; Schulz-Rothe S; Koné I; Gerlach FM
    BMC Cancer; 2015 Aug; 15():605. PubMed ID: 26314581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
    Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
    Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial.
    Sali L; Ventura L; Mascalchi M; Falchini M; Mallardi B; Carozzi F; Milani S; Zappa M; Grazzini G; Mantellini P
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1016-1023. PubMed ID: 36116454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.